

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

**POSTPONEMENT OF EXTRAORDINARY GENERAL MEETING
AND
WITHDRAWAL OF THE ORDINARY RESOLUTION**

References are made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”) dated 30 August 2022 regarding the 2022 Share Option Scheme and the EGM which was originally scheduled to be held on Wednesday, 21 September 2022 at 10:00 a.m. Unless otherwise stated, capitalised terms used herein shall have the same meaning as defined in the Circular.

The Circular was uploaded on the Stock Exchange website on 30 August 2022 after the routine regulatory pre-vetting. Subsequently, the Company received enquiry from the Stock Exchange, requesting that the 2022 Share Option Scheme be revised with reference to the new Chapter 17 of the Listing Rules taking effect on 1 January 2023. As such, additional time is required to prepare for the EGM the holding of which will be postponed to a later date to be announced. The register of members of the Company will not be closed from Thursday, 15 September 2022 to Wednesday, 21 September 2022 as originally scheduled.

The ordinary resolution set out in the Notice is hereby withdrawn. The Notice and the Circular are no longer applicable. Proxy forms completed and delivered (based on the proxy form published by the Company on 30 August 2022) will no longer be valid for the postponed EGM. Shareholders are required to submit new proxy forms based on the proxy form to be published by the Company for use at the postponed EGM.

The Company will make separate announcement as soon as practicable to inform the Shareholders of the detailed arrangement for the postponed EGM as well as any other matters relating to the postponed EGM.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 14 September 2022

As at the date of this announcement, the executive director is Dr. Shui On LEUNG, the non-executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.